Samsung Biologics to Construct New Manufacturing Facility for Next-Gen Vaccines and CGT

Samsung Biologics is planning to construct a new manufacturing facility in Incheon, South Korea, that will offer multi-product manufacturing, including cell and gene therapies and next-gen vaccines.

Samsung Biologics announced on Jan. 12, 2022 that it plans to start building a new facility (designated Plant 5) at Songdo in Incheon, South Korea, this year. The facility will offer manufacturing for multi-modal products, including cell and gene therapies and next-generation vaccines that utilize messenger RNA (mRNA), plasmid DNA, and viral vectors. The expansion is part of the company’s 2022 growth plan.

The new facility will be an addition to the mRNA vaccine drug substance (DS) manufacturing suite that the company is currently adding to its existing facility in Songdo. The mRNA vaccine DS facility is expected to be ready for current good manufacturing practice operations within the earlier part of this year, according to a company press release.

Samsung Biologics is further looking to secure additional sites within Songdo for the future construction of another additional facility (designated Plant 6) and an open innovation center. In addition, the company is looking for overseas sites in multiple locations to maximize both its manufacturing capacity for producing large-scale biologics and to be in close proximity to global clients.

Samsung Biologics’ Plant 4 is currently under construction and is expected to be partially operational by the end of this year. When Plant 4 is fully completed in 2023, the company expects to have a total capacity of 620,000 L.

“Through proactive investment in increasing our manufacturing capacity, enhancing portfolio diversification, and expanding facilities in overseas, Samsung Biologics will be able to accelerate the build-up of its core success drivers as the next growth engine of the industry,” said John Rim, CEO of Samsung Biologics, in a company press release.

Source: Samsung Biologics